Jacek Hajda

1.1k total citations
14 papers, 540 citations indexed

About

Jacek Hajda is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Jacek Hajda has authored 14 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 6 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Jacek Hajda's work include Virus-based gene therapy research (7 papers), CAR-T cell therapy research (4 papers) and Cancer Research and Treatments (4 papers). Jacek Hajda is often cited by papers focused on Virus-based gene therapy research (7 papers), CAR-T cell therapy research (4 papers) and Cancer Research and Treatments (4 papers). Jacek Hajda collaborates with scholars based in Germany, Norway and Austria. Jacek Hajda's co-authors include Jean Rommelaere, Barbara Leuchs, Karsten Geletneky, Ottheinz Krebs, Michael Dahm, Bernard Huber, Johannes Hüsing, Werner Hacke, Julian Bösel and Thorsten Steiner and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Neurology and European Journal of Cancer.

In The Last Decade

Jacek Hajda

14 papers receiving 526 citations

Peers

Jacek Hajda

GENET

ONCOL

NEURO

EPIDE

Abdallah Naya Morocco

Duoduo Han China

Juping Du China

Satoshi Ochi Japan

Maya Margalit Israel

Dragana Jugović Austria

Abdus Saleem United States

Zhihong Zuo China

Ana M. Santander United States

Tsunao Oh‐i Japan

Abdallah Naya Morocco

Jacek Hajda

38 ×0.2

GENET

91 ×0.6

ONCOL

119 ×0.8

NEURO

61 ×0.4

EPIDE

164 ×1.4

Citations per year, relative to Jacek Hajda Jacek Hajda (= 1×) peers Abdallah Naya

Countries citing papers authored by Jacek Hajda

Since Specialization

Citations

This map shows the geographic impact of Jacek Hajda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacek Hajda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacek Hajda more than expected).

Fields of papers citing papers by Jacek Hajda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacek Hajda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacek Hajda. The network helps show where Jacek Hajda may publish in the future.

Co-authorship network of co-authors of Jacek Hajda

This figure shows the co-authorship network connecting the top 25 collaborators of Jacek Hajda. A scholar is included among the top collaborators of Jacek Hajda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacek Hajda. Jacek Hajda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Sauer, Sandra, Johannes Hüsing, Jacek Hajda, et al.. (2018). A prospective study on serum Cytokeratin (CK)-18 and CK18 fragments as biomarkers of acute hepato-intestinal GVHD. Leukemia. 32(12). 2685–2692. 7 indexed citations

Hajda, Jacek, Ottheinz Krebs, Meinhard Kieser, et al.. (2017). A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. BMC Cancer. 17(1). 576–576. 40 indexed citations

Schmitt, Thomas, Regine Mayer‐Steinacker, Frank Mayer, et al.. (2016). Vorinostat in refractory soft tissue sarcomas – Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). European Journal of Cancer. 64. 74–82. 32 indexed citations

Steiner, Thorsten, Sven Poli, Martin Griebe, et al.. (2016). Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. The Lancet Neurology. 15(6). 566–573. 219 indexed citations

Geletneky, Karsten, Barbara Leuchs, Karin Jochims, et al.. (2015). Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1.. PubMed. 65(1). 23–35. 13 indexed citations

Geletneky, Karsten, Barbara Leuchs, Karin Jochims, et al.. (2015). Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats.. PubMed. 65(1). 36–45. 14 indexed citations

Geletneky, Karsten, Assia L. Angelova, Barbara Leuchs, et al.. (2015). ATNT-07FAVORABLE RESPONSE OF PATIENTS WITH GLIOBLASTOMA AT SECOND OR THIRD RECURRENCE TO REPEATED INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB. Neuro-Oncology. 17(suppl 5). v11.3–v11. 9 indexed citations

Geletneky, Karsten, Assia L. Angelova, Barbara Leuchs, et al.. (2014). ET-21 * COMBINATION OF INTRAVENOUS AND INTRACEREBRAL INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN A PHASE I/IIA CLINICAL TRIAL OF PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: PENETRATION OF H-1 VIRUS ACROSS THE BLOOD-BRAIN BARRIER. Neuro-Oncology. 16(suppl 5). v83–v84. 4 indexed citations

Geletneky, Karsten, Johannes Huesing, Michael Dahm, et al.. (2014). First combined intravenous and intracerebral application of an oncolytic virus, parvovirus h-1, in a phase I/IIa clinical trial in patients with recurrent glioblastoma multiforme (ParvOryx01).. Journal of Clinical Oncology. 32(15_suppl). TPS2111–TPS2111. 1 indexed citations

10.

Geletneky, Karsten, Johannes Huesing, Jean Rommelaere, et al.. (2012). Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer. 12(1). 99–99. 130 indexed citations

11.

Habl, Gregor, Alexandra D Jensen, Karin Potthoff, et al.. (2010). Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol. BMC Cancer. 10(1). 651–651. 7 indexed citations

12.

Hajda, Jacek, Katharina Rentsch, Christoph Gubler, et al.. (2010). Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. European Journal of Pharmaceutical Sciences. 41(5). 729–735. 45 indexed citations

13.

Moehler, Thomas, Reinhard Feneberg, Anthony D. Ho, et al.. (2010). Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma. Anti-Cancer Drugs. 21(7). 708–715. 6 indexed citations

14.

Hajda, Jacek, E. Jähnchen, Svein Øie, & Dietmar Trenk. (2002). Sequential First‐Pass Metabolism of Nortilidine: The Active Metabolite of the Synthetic Opioid Drug Tilidine. The Journal of Clinical Pharmacology. 42(11). 1257–1261. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact